By Helena SmolakIpsen's phase-three trial of prostate cancer drug Cabometyx yielded positive results, the company said late Monday. The French biopharmaceutical company said that its phase-three trial has shown progression-free survival benefits for the combination of the chemotherapy drug Cabometyx and the immunotherapy drug atezolizumab in metastatic castration-resistant prostate cancer. It will present findings at the upcoming American Society of Clinical Oncology Genitourinary Symposium on Jan. 25-27 in San Francisco. The company's four-year trial demonstrated that the combination of Cabometyx(R) and nivolumab continues to provide long-term benefits in treating advanced renal cell carcinoma, compared to the anti-cancer medication sunitinib, it said. Write to Helena Smolak at helena.smolak@wsj.com

Source: Wall Street Journal January 23, 2024 08:49 UTC